Moderna’s investigational vaccine is being evaluated in a mid-stage trial with Merck’s breakthrough cancer immunotherapy, Keytruda, to treat patients with melanoma, the deadliest type of skin cancer. The vaccine, mRNA-4157, will be studied in the fourth quarter of this year.
Moderna has pinned its hopes on its non-COVID vaccines, which include influenza and respiratory syncytial virus shots, with the size of the COVID-19 vaccine market expected to contract in subsequent years from levels seen in 2021.
Based on the specific mutational signature of a tumour, the cancer vaccine is tailored for each patient to generate T-cells, a critical component of the body’s immune response.
Merck and Moderna formed a strategic alliance in 2016 to develop a personalised vaccine for the treatment of various types of cancer.
Merck sold its equity stake in Moderna in 2020, benefiting from a surge in the vaccine maker’s stock price that year.
Read More :- COUGH SYRUPS REASON BEHIND DEATHS IN INDIA
